Nexien BioPharma, Inc. (NXEN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nexien BioPharma, Inc. (NXEN) trades at $0.00 with AI Score 50/100 (Grade B). Nexien BioPharma, Inc. is a pharmaceutical company based in Glendale, Colorado, focused on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals. Market cap: $7,077, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for NXEN: NXEN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NXEN against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
NXEN: the 1 perspectives are evenly split.
How is this calculated? →Nexien BioPharma, Inc. (NXEN) Healthcare & Pipeline Overview
Nexien BioPharma, Inc. is a Glendale, Colorado-based pharmaceutical company specializing in the formulation, development, and commercialization of cannabinoid-based pharmaceuticals. It navigates pre-clinical and clinical pathways to address a range of diseases and medical conditions, positioning itself within the evolving specialty drug manufacturing sector.
What Is the Investment Thesis for NXEN?
Nexien BioPharma, Inc. is positioned within the specialized and evolving cannabinoid-based pharmaceutical market, focusing on the rigorous pre-clinical and clinical development of new drug candidates. The company's value drivers are intrinsically linked to its ability to successfully advance its pipeline through various clinical trial stages, culminating in regulatory approvals and subsequent commercialization. Key growth catalysts include positive data readouts from ongoing or future clinical trials, which could significantly de-risk its development programs and attract further investment or partnerships. Expansion into new therapeutic indications for its cannabinoid-based formulations also represents a substantial growth opportunity. However, the company operates with a market capitalization of 7K and a negative Beta of -0.85, indicating a micro-cap status and potentially inverse market correlation, which suggests high volatility and specific risk factors. Its status as an OTC-traded company, specifically on the 'OTC Other' tier, also introduces risks related to liquidity and disclosure. The investment thesis centers on the long-term potential of its specialized drug development efforts, contingent on achieving significant milestones in a highly regulated and capital-intensive industry.
Based on FMP financials and quantitative analysis
NXEN Key Highlights
- Specialized focus on cannabinoid-based pharmaceuticals development, targeting various diseases and medical conditions.
- Operates within the pre-clinical and clinical pathways, indicating a long-term R&D-intensive business model.
- Company rebranded from Intiva BioPharma Inc. to Nexien BioPharma, Inc. in September 2018, signaling strategic evolution.
- Trades on the OTC market under the 'OTC Other' tier, reflecting its current market structure and disclosure environment.
- Reported market capitalization of 7K, highlighting its micro-cap status within the pharmaceutical sector.
Who Are NXEN's Competitors?
NXEN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NXEN's Key Strengths?
- Specialized focus on cannabinoid-based pharmaceuticals, a growing therapeutic area.
- Engagement in pre-clinical and clinical pathways, indicating a structured drug development approach.
- Potential for novel drug formulations addressing unmet medical needs.
- Agile structure as a smaller pharmaceutical company to adapt to market changes.
What Are NXEN's Weaknesses?
- Market capitalization of 7K suggests limited financial resources for extensive R&D.
- Trading on the 'OTC Other' tier implies lower liquidity and transparency compared to major exchanges.
- Negative Beta of -0.85 indicates high volatility and potential inverse market correlation.
- Reliance on successful progression through lengthy and costly clinical trials.
What Could Drive NXEN Stock Higher?
- Positive results from pre-clinical studies for a lead cannabinoid-based drug candidate, demonstrating efficacy or safety in initial models.
- Initiation of a Phase 1 clinical trial for a novel cannabinoid formulation, marking a significant step in human testing.
- Announcement of a strategic partnership or collaboration with a larger pharmaceutical entity to co-develop or fund a pipeline asset.
- Continuous research and development efforts to identify new therapeutic targets for cannabinoid compounds, expanding the company's intellectual property portfolio.
What Are the Key Risks for NXEN?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- High regulatory hurdles and lengthy approval processes inherent in pharmaceutical development, particularly for cannabinoid-based drugs.
- Significant capital requirements for pre-clinical and clinical trials, with a risk of insufficient funding given the 7K market cap.
- Intense competition from established pharmaceutical companies and other biotech firms in the cannabinoid therapeutics space.
- Low liquidity and limited public disclosure associated with trading on the 'OTC Other' tier, posing challenges for investors.
- Clinical trial failures or adverse safety findings, which could lead to abandonment of drug candidates and substantial financial losses.
What Are the Growth Opportunities for NXEN?
- Growth opportunity 1: Advancing its cannabinoid-based drug candidates through clinical trials represents a primary growth driver. Successful progression from pre-clinical stages to Phase 1, 2, and 3 trials, followed by regulatory approval, would unlock significant market potential. The global cannabinoid therapeutics market is projected to grow substantially, driven by increasing research into their medical applications and changing legal landscapes. Each successful clinical milestone de-risks the asset and increases its valuation, potentially attracting partnerships or acquisition interest, and opening pathways to address specific disease markets with unmet needs. This timeline is typically long-term, spanning several years per drug candidate.
- Growth opportunity 2: Expanding the therapeutic indications for its existing or pipeline cannabinoid formulations. If a drug candidate initially developed for one condition shows promise for others, pursuing additional indications can significantly broaden its addressable market. For instance, a compound effective in pain management might also be explored for neurological disorders or inflammatory conditions. This strategy leverages existing R&D investment and intellectual property, potentially accelerating market penetration and revenue generation. The market for specific therapeutic areas, such as chronic pain or epilepsy, can be multi-billion dollars annually, offering substantial targets for expanded indications.
- Growth opportunity 3: Strategic partnerships and collaborations with larger pharmaceutical companies. Given the capital-intensive nature of drug development, securing partnerships can provide crucial funding, access to broader R&D capabilities, and established commercialization infrastructure. These collaborations can accelerate drug development timelines, reduce financial risk, and enhance market reach. Such partnerships often involve upfront payments, milestone payments, and royalty streams, providing non-dilutive capital and future revenue potential. This is a medium to long-term opportunity, contingent on the strength of Nexien's pipeline assets.
- Growth opportunity 4: Intellectual property expansion and portfolio diversification within the cannabinoid space. Continuously innovating and securing patents for novel formulations, delivery methods, or specific cannabinoid compounds can create a strong competitive moat. Diversifying its portfolio to include a range of cannabinoid derivatives or synthetic cannabinoids can also mitigate risks associated with any single compound's failure and open up new market segments. The market for patented cannabinoid-based drugs is distinct from the broader cannabis market, offering higher margins and greater exclusivity, with long-term protection extending for decades.
- Growth opportunity 5: Navigating and adapting to evolving regulatory landscapes for cannabinoid-based medicines. As more jurisdictions legalize or regulate medical cannabis and cannabinoid-derived pharmaceuticals, the market access opportunities expand. Proactively engaging with regulatory bodies and ensuring compliance can position Nexien BioPharma to enter new geographic markets or benefit from favorable regulatory changes. The global regulatory environment is dynamic, and companies that can adeptly navigate these changes stand to gain significant first-mover or early-adopter advantages in newly opened markets, potentially unlocking billions in new market segments over the next 5-10 years.
What Opportunities Does NXEN Have?
- Expanding global acceptance and legalization of medical cannabinoids creating new markets.
- Discovery of new therapeutic applications for cannabinoid compounds.
- Potential for strategic partnerships with larger pharmaceutical companies for funding and distribution.
- Innovation in drug delivery methods or synthetic cannabinoid development.
What Threats Does NXEN Face?
- Intense competition from larger pharmaceutical companies entering the cannabinoid space.
- Strict and evolving regulatory hurdles for cannabinoid-based drugs.
- High failure rates inherent in pharmaceutical R&D, leading to significant capital loss.
- Limited access to capital markets due to OTC listing and small market cap.
What Are NXEN's Competitive Advantages?
- Specialized expertise in cannabinoid formulation and development.
- Potential intellectual property (patents) protecting its drug candidates and processes.
- Regulatory know-how and experience in navigating pharmaceutical approval pathways.
- Early-mover advantage or established position in the emerging cannabinoid pharmaceutical market.
What Does NXEN Do?
Nexien BioPharma, Inc., headquartered in Glendale, Colorado, operates as a pharmaceutical company dedicated to advancing cannabinoid-based therapeutics. The company's core activities encompass the formulation, development, and eventual commercialization of these specialized pharmaceuticals. Its strategic focus involves navigating the rigorous pre-clinical and clinical trial pathways required for regulatory approval, with the ultimate goal of bringing novel treatments to market for a diverse array of diseases, medical conditions, and disorders. The company's journey began under the name Intiva BioPharma Inc., before undergoing a strategic rebranding and changing its name to Nexien BioPharma, Inc. in September 2018. This name change marked a pivotal moment in its corporate evolution, signaling a refined focus or expanded scope within the biopharmaceutical landscape. Nexien BioPharma's operational model is deeply rooted in research and development, aiming to unlock the therapeutic potential of cannabinoids, which represent a distinct and increasingly recognized area within modern medicine. By concentrating on this niche, the company positions itself within the specialty pharmaceutical segment, requiring significant investment in scientific expertise, regulatory compliance, and clinical validation to establish its product pipeline and market presence. Its efforts are directed towards addressing unmet medical needs through innovative drug candidates, contributing to the broader healthcare sector's advancements.
What Products and Services Does NXEN Offer?
- Formulates cannabinoid-based pharmaceuticals for medical applications.
- Develops new drug candidates through pre-clinical research.
- Conducts clinical trials to test the safety and efficacy of its pharmaceutical products.
- Aims for commercialization of approved cannabinoid-based drugs.
- Focuses on treating various diseases, medical conditions, and disorders.
- Operates within the highly regulated pharmaceutical industry.
- Specializes in a niche area of drug manufacturing: cannabinoid therapeutics.
How Does NXEN Make Money?
- Research and development of cannabinoid-based drug candidates.
- Seeking regulatory approvals (e.g., FDA) for its pharmaceutical products.
- Potential commercialization and sales of approved drugs, either directly or through partnerships.
- Monetization of intellectual property through licensing or milestone payments from collaborations.
What Industry Does NXEN Operate In?
Nexien BioPharma, Inc. operates within the Drug Manufacturers - Specialty & Generic industry, with a distinct focus on cannabinoid-based pharmaceuticals. This segment of the healthcare sector is characterized by high research and development costs, stringent regulatory pathways, and significant intellectual property considerations. The broader pharmaceutical market is experiencing trends such as increasing demand for personalized medicine, a shift towards biologics and specialty drugs, and growing investment in novel therapeutic areas. Within this landscape, cannabinoid-based therapeutics represent an emerging, yet rapidly expanding, niche driven by evolving scientific understanding and regulatory frameworks. Nexien BioPharma's positioning as a developer in this specific area places it among companies seeking to capitalize on the therapeutic potential of cannabinoids, competing not only with other cannabinoid-focused firms but also with established pharmaceutical giants that may enter or acquire assets in this space. The competitive environment demands continuous innovation, efficient clinical execution, and strategic market access planning.
Who Are NXEN's Key Customers?
- Patients suffering from diseases and conditions treatable by cannabinoid-based pharmaceuticals.
- Healthcare providers (doctors, hospitals) prescribing or administering its approved drugs.
- Pharmaceutical distributors and pharmacies for product distribution.
- Potential pharmaceutical partners for co-development or licensing agreements.
ROE 0%Key Financial Metrics
Return on equity for Nexien BioPharma, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching.
Nexien BioPharma, Inc. (NXEN) Valuation Context
Valued at 7K, NXEN is classified as a micro-cap stock. Relative to its peer group, NXEN's quantitative score of 50/100 is below the peer average of 66/100.
Company Profile
Nexien BioPharma, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Glendale, US. The company is led by CEO Richard S. Greenberg. NXEN has traded publicly since 2017.
F-Score 1/9Financial Health
Nexien BioPharma, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
NXEN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Nexien's insider buying suggests strong confidence in the company's future prospects, signaling potential growth.
- The buzz in the social trading community is optimistic about Nexien's strategic partnerships and potential market expansion.
- Positive sentiment indicates the community believes Nexien is undervalued and poised for a breakout.
- Recent market developments suggest increased investor appetite for biotech companies like Nexien, potentially driving up demand.
Bear Case
- Lack of clear communication from Nexien's management is raising concerns about transparency and future direction.
- The social trading community is expressing skepticism about Nexien's ability to execute its long-term strategy effectively.
- Bearish views highlight concerns about increased competition in Nexien's target market, potentially impacting market share.
- Recent market volatility is creating uncertainty about Nexien's short-term performance, making investors cautious.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NXEN Latest News
No recent news available for NXEN.
NXEN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NXEN.
Price Targets
Wall Street price target analysis for NXEN.
NXEN MoonshotScore
What does this score mean?
The MoonshotScore rates NXEN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Richard S. Greenberg
Chief Executive Officer
Unknown
Track Record: Unknown
NXEN OTC Market Information
Nexien BioPharma, Inc. trades on the 'OTC Other' tier, which represents the lowest tier of the OTC Markets Group's three marketplaces. Unlike companies listed on major exchanges like NYSE or NASDAQ, 'OTC Other' companies do not meet minimum financial standards, disclosure requirements, or corporate governance standards to qualify for OTCQX or OTCQB. This tier includes companies that may not be current in their disclosures or have limited public information available. Investors typically face higher risks due to the lack of transparent financial reporting and regulatory oversight compared to higher tiers or listed exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure and transparency, making due diligence challenging.
- Extremely low trading volume and liquidity, leading to difficulty in buying or selling shares.
- Increased susceptibility to market manipulation due to low float and limited oversight.
- Higher volatility and price fluctuations compared to stocks on major exchanges.
- Potential for delisting or further deterioration of trading status if disclosure remains unknown or inadequate.
- Verify the company's current financial statements and audit reports, if available, from independent sources.
- Research any recent corporate actions, such as reverse stock splits or share issuances, that could impact ownership.
- Investigate the management team's background and track record beyond what is publicly stated.
- Assess the viability and progress of its cannabinoid-based pharmaceutical pipeline through independent scientific reviews.
- Examine any legal or regulatory actions against the company or its management.
- Understand the current shareholder structure and any significant institutional holdings.
- Evaluate the company's capital raising history and future funding needs.
- The company has a stated focus on a specific, albeit emerging, pharmaceutical segment (cannabinoid-based drugs).
- It has undergone a formal name change, indicating some level of corporate activity and strategic evolution.
- The company is headquartered in Glendale, Colorado, suggesting a physical operational base.
- Its stated pursuit of pre-clinical and clinical pathways aligns with standard pharmaceutical development processes.
- The presence of a named CEO, Richard S. Greenberg, provides a point of contact for leadership.
Nexien BioPharma, Inc. Healthcare Stock: Key Questions Answered
What does Nexien BioPharma, Inc. do?
Nexien BioPharma, Inc. is a pharmaceutical company based in Glendale, Colorado, specializing in the formulation, development, and commercialization of cannabinoid-based pharmaceuticals. The company's primary objective is to advance these specialized drugs through rigorous pre-clinical and clinical pathways to treat a range of diseases, medical conditions, and disorders. Its business model is centered on research and development, aiming to bring innovative cannabinoid therapeutics to market, thereby addressing specific unmet medical needs within the broader healthcare sector. The company was formerly known as Intiva BioPharma Inc. before its name change in September 2018.
What is Nexien BioPharma, Inc.'s drug pipeline status?
Nexien BioPharma, Inc. is actively engaged in the pre-clinical and clinical pathways for its cannabinoid-based pharmaceuticals. While specific details on individual drug candidates or their current phase (e.g., Phase 1, 2, or 3) are not provided in the available information, the company's stated focus indicates ongoing research and development. Progression through these stages is critical for any pharmaceutical company, as successful clinical trial completion and regulatory approval are necessary before commercialization. Investors typically look for updates on specific drug candidates, their target indications, and their advancement through the various clinical trial phases as key indicators of pipeline health and future potential.
What are the main risks for NXEN?
Nexien BioPharma, Inc. faces several significant risks inherent to its industry and market position. As a pharmaceutical company, it is exposed to the high costs, long timelines, and high failure rates associated with drug development and clinical trials. Regulatory hurdles for cannabinoid-based drugs are particularly stringent and can evolve, posing additional challenges. Financially, its 7K market capitalization suggests limited resources, raising concerns about its ability to fund extensive R&D without significant external capital. Furthermore, trading on the 'OTC Other' tier means lower liquidity, minimal disclosure, and increased susceptibility to market volatility and manipulation, all of which present substantial risks for investors.
How does Nexien BioPharma, Inc. manage patent expiration risks?
While specific strategies for managing patent expiration risks are not detailed in the provided information, for a pharmaceutical company like Nexien BioPharma, Inc. focused on novel drug development, intellectual property protection is paramount. Typically, companies in this sector manage patent expiration through several strategies. These include continuously investing in new research to discover and patent next-generation compounds or improved formulations, developing proprietary drug delivery systems, and pursuing new indications for existing drugs to extend their market exclusivity. Given its focus on cannabinoid-based pharmaceuticals, securing robust patents for its unique formulations and therapeutic applications would be a critical component of its long-term strategy to mitigate future patent cliff exposure and competition from generics or biosimilars.
What are the key factors to evaluate for NXEN?
Nexien BioPharma, Inc. (NXEN) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does NXEN data refresh on this page?
NXEN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NXEN's recent stock price performance?
Nexien BioPharma, Inc. (NXEN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on cannabinoid-based pharmaceuticals, a growing therapeutic area. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NXEN overvalued or undervalued right now?
Valuing Nexien BioPharma, Inc. (NXEN) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available, particularly for specific revenue, profit, or balance sheet metrics beyond market cap.
- CEO background and track record are not provided in the source data, leading to 'Unknown' entries.
- Competitor information (FMP PEER TICKERS) was not provided, resulting in an empty array for competitors.
- Specific details on drug pipeline stages (e.g., Phase 1, 2, 3) are not available in the source data, requiring general statements about pre-clinical and clinical pathways.